Chikungunya virus: Update on molecular biology, epidemiology and current strategies

  • Debora Stelitano Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Annalisa Chianese Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Roberta Astorri Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Enrica Serretiello Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Carla Zannella Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Veronica Folliero Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Marilena Galdiero Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Gianluigi Franci Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Valeria Crudele Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Mariateresa Vitiello | mteresa.vitiello@gmail.com Department of Clinical Pathology, Virology Unit, San Giovanni di Dio e Ruggi d’Aragona Hospital, Salerno, Italy.

Abstract

Chikungunya virus (CHIKV), an arthropod-borne virus, is the aetiological agent of a disease characterized by several aspecific symptoms including fever, myalgia and arthralgia. The virus is primarily transmitted to humans through the bite of an infected mosquito of Aedes genus. This virus was first isolated in Tanzania in 1953, from which it spread to other African countries, Asia, Northern and Southern America, Europe and Oceania. Today, many human cases of CHIKV infection have been identified. The diffusion of CHIKV across the world, including Italy, is due to multiple factors amongst which the wide distribution of its vectors and high transmission efficiency play a crucial role. Currently, there are no specific treatments and effective vaccines against CHIKV; indeed, available therapies allow symptoms mitigation and some promising vaccines are undergoing clinical trials. The purpose of this review is to offer an updated picture of CHIKV molecular biology, epidemiology and vector distribution, clinical features and strategies for infection prevention and treatment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-06-20
Info
Issue
Section
Review Articles
Supporting Agencies
VALEREplus program
Keywords:
Chikungunya virus, Life cycle, Epidemiology, Vector, Clinical management
Statistics
  • Abstract views: 474

  • PDF: 233
How to Cite
Stelitano, D., Chianese, A., Astorri, R., Serretiello, E., Zannella, C., Folliero, V., Galdiero, M., Franci, G., Crudele, V., & Vitiello, M. (2019). Chikungunya virus: Update on molecular biology, epidemiology and current strategies. Translational Medicine Reports, 3(1). https://doi.org/10.4081/tmr.8156

Most read articles by the same author(s)